Yes, your body naturally produces glucagon-like peptide-1 (GLP-1), a hormone that plays a crucial role in regulating blood sugar levels and appetite
The question many researchers are asking is whether a similar jump in results will occur when transitioning from tirzepatide to retatrutide, thanks to that glucagon component
Currently, Wegovy is FDA approved for the following: Children ages 12 years or older with a body mass index (BMI) at or above the 95th percentile for their sex and age Adults with a BMI at or above 30 Adults with a BMI at or above 27 and at least one weight-related health condition, such as heart disease, diabetes, high blood pressure, or sleep apnea Adults with a BMI at or above 27 with established cardiovascular disease and a risk of major adverse cardiovascular events (like heart attack or stroke) Adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis Note that there are slightly different prescribing rules for Wegovy pills versus Wegovy injections
these can then be managed in a structured way
Moreover, it is not possible to clarify whether these effects are fully secondary to weight reduction and if this drug class has other beneficial hepatocellular activities beyond weight loss